A
Acarix AB
STO:ACARIX
Acarix AB
STO:ACARIX
Price:
0.3
SEK
7.33%
Market Closed
Market Cap:
kr337m
Relative Value
The Relative Value of one ACARIX stock under the Base Case scenario is 0.03 SEK. Compared to the current market price of 0.3 SEK, Acarix AB is Overvalued by 91%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
ACARIX
Relative Value
Base Case
0.03
SEK
Overvaluation 91%
A
Multiples Across Competitors
ACARIX Competitors Multiples
Acarix AB Competitors
Acarix AB Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| SE |
A
|
Acarix AB
STO:ACARIX
|
349.4m SEK | 47.5 | -7.3 | -7.4 | -6.9 | |
| US |
|
Abbott Laboratories
NYSE:ABT
|
190.9B USD | 4.3 | 29.3 | 16.8 | 23 | |
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
171.7B USD | 17.1 | 60.1 | 45.6 | 56 | |
| US |
|
Stryker Corp
NYSE:SYK
|
133.7B USD | 5.3 | 41.2 | 21 | 25.4 | |
| IE |
|
Medtronic PLC
NYSE:MDT
|
113.2B USD | 3.2 | 24.5 | 13.5 | 19.7 | |
| US |
|
Boston Scientific Corp
NYSE:BSX
|
103.5B USD | 5.2 | 35.7 | 21 | 28.2 | |
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
43.3B EUR | 1.9 | 20.5 | 11.4 | 16.1 | |
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
48.5B USD | 8 | 45.2 | 24.9 | 27.3 | |
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
46.7B USD | 10.9 | 44.1 | 31.3 | 34.6 | |
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
45.6B USD | 2.1 | 26 | 10.2 | 17.2 | |
| US |
|
Resmed Inc
NYSE:RMD
|
33.6B USD | 6.2 | 22.6 | 15.9 | 17.7 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
